e-learning
resources
Virtual 2020
Wednesday, 09.09.2020
Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Acute exacerbation in combined pulmonary fibrosis and emphysema (CPFE): what special features?
H. Mrassi (Tunis, Tunisia), I. Bachouch (Tunis, Tunisia), N. Belloumi (Tunis, Tunisia), F. Chermiti (Tunis, Tunisia), S. Fenniche (Tunis, Tunisia)
Source:
Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases
Session:
Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases
Session type:
Oral Presentation
Number:
5256
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Mrassi (Tunis, Tunisia), I. Bachouch (Tunis, Tunisia), N. Belloumi (Tunis, Tunisia), F. Chermiti (Tunis, Tunisia), S. Fenniche (Tunis, Tunisia). Acute exacerbation in combined pulmonary fibrosis and emphysema (CPFE): what special features?. 5256
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Related content which might interest you:
Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Acute exacerbation of idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 792
Year: 2004
Clinical features of combined pulmonary fibrosis and emphysema
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009
Combined pulmonary fibrosis and emphysema (CPFE): How does cohabitation affect respiratory functions?
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
Source: Eur Respir J 2015; 46: 512-520
Year: 2015
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Combined pulmonary fibrosis and emphysema: A distinct entity?
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features
Source: Eur Respir J 2006; 27: 143-150
Year: 2006
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
Does emphysema coexistence with IPF change prognosis?
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016
Year: 2017
Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features?
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Comparison of clinical features between patients of lung cancer with combined pulmonary fibrosis and emphysema syndrome and those with interstitial pneumonia
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept